Asked about the US's Right to Try law, Center for Biologics Evaluation and Research Director Peter Marks said he needed to "carefully side-step" the issue, but he was willing to discuss what he called a surrogate marker for the new framework.
During the Nov. 14 Biopharma Congress IV, sponsored by Prevision Policy and the Friends of Cancer Research, he was queried...